Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with radiotherapy for recurrent or advanced recurrent colorectal cancer
ChiCTR2100053487Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Started Nov 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100053487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053487.